Fig 1: PLTP binds to P65 and cooperates with AURKA to promote P65 nuclear translocation and NF‐κB activation. A) Immunofluorescence analysis showing that PLTP overexpression promotes nuclear translocation of P65. Scale bar: 50 µm. B) Western blot analysis revealing increased nuclear levels of P65 upon PLTP overexpression. C) Immunofluorescence co‐localization analysis showing subcellular co‐localization of PLTP and P65. Scale bar: 10 µm. D) Co‐immunoprecipitation (Co‐IP) assay confirming the interaction between PLTP and P65. E) Mass spectrometry analysis identifying the top five candidate proteins potentially interacting with PLTP. F) Chromatographic profile of AURKA identified by mass spectrometry. G) The 3D spatial pattern of PLTP combined with P65 and AURKA, blue representing PLTP, green representing P65 (left) and AURKA (right), and red indicating the binding regions. H) Immunofluorescence analysis showing co‐localization of PLTP and AURKA. Scale bar: 10 µm. I) Co‐IP assay confirming the interaction between PLTP and AURKA.
Fig 2: PLTP functions as an intermediary for AURKA‐mediated P65 phosphorylation and can be targeted by GMB‐475. A) Exogenous and endogenous Co‐IP assays show that PLTP simultaneously interacts with both AURKA and P65. B) Knockdown of AURKA abolishes PLTP‐induced phosphorylation of P65. C) In vitro kinase assay demonstrating that P65 is a direct phosphorylation substrate of AURKA. D) Schematic of PLTP functional domain prediction by the SMART database and the design of domain‐specific PLTP truncation plasmids. E) Co‐IP experiments identifying the binding domains of PLTP responsible for interaction with AURKA and P65. F) Molecular docking analysis of GMB‐475 with PLTP: (a) Overall 3D view showing GMB‐475 with carbon atoms in magenta, oxygen in red, nitrogen in blue, and the protein in green cartoon representation. (b) Enlarged 3D view showing interactions between GMB‐475 and surrounding amino acid residues. Yellow dashed lines represent hydrogen bonds, red dashed lines indicate ionic bonds, and dashed purple lines indicate aromatic ring–hydrogen stacking. (c) 2D interaction map indicating hydrogen bonds (arrows) and aromatic stacking (dashed lines). G) Co‐IP assays demonstrate that GMB‐475 disrupts the interaction of PLTP with both AURKA and P65. H) Representative tumor images from different treatment groups: Hepa1‐6‐NC + PBS; Hepa1‐6‐PLTP + PBS; Hepa1‐6‐PLTP + GMB‐475. I, J) Tumor weight (I) and growth rate (J) comparisons across treatment groups. K) Representative IHC images of tumor sections showing reduced M2 macrophage infiltration (CD163+, CD206+) and enhanced CD8+ T‐cell infiltration following GMB‐475 treatment. Scale bar: 50 µm (magnification ×200). L) Quantification of CD8+ cells by IHC in subcutaneous tumor tissues from C57BL/6J mice. *P < 0.05, **P < 0.01, ***P < 0.001.
Supplier Page from Abcam for Recombinant human Aurora A protein (Active) (His tag N-Terminus)